Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Rockwell Medical (RMTI) over the last 6 years, with Sep 2025 value amounting to $124,000.

  • Rockwell Medical's Gains from Investment Securities fell 11.43% to $124,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $446,000, marking a year-over-year decrease of 64.49%. This contributed to the annual value of $2.0 million for FY2024, which is 83.24% up from last year.
  • Rockwell Medical's Gains from Investment Securities amounted to $124,000 in Q3 2025, which was down 16.22% from $148,000 recorded in Q2 2025.
  • Rockwell Medical's Gains from Investment Securities' 5-year high stood at $840,000 during Q3 2023, with a 5-year trough of $10,000 in Q2 2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $138,000 (2024), whereas its average is $196,000.
  • Per our database at Business Quant, Rockwell Medical's Gains from Investment Securities soared by 1,200.00% in 2023 and then slumped by 83.33% in 2024.
  • Quarterly analysis of 5 years shows Rockwell Medical's Gains from Investment Securities stood at $57,000 in 2021, then spiked by 431.58% to $303,000 in 2022, then spiked by 182.83% to $840,000 in 2023, then plummeted by 83.33% to $28,000 in 2024, then fell by 11.43% to $124,000 in 2025.
  • Its last three reported values are $124,000 in Q3 2025, $148,000 for Q2 2025, and $146,000 during Q1 2025.